GlassScriptPhysician profile
Robert C Schwartz
NPI 1063501559
$2,448.90
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,850 · 2020: $452 · 2021: $84.90 · 2022: $61.79.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $293.55 | 2019-2020 | |
| Pfizer INC. | $245.83 | 2019-2020 | |
| Novo Nordisk INC | $239.79 | 2019-2020 | |
| Amgen INC. | $233.59 | 2019-2020 | |
| Abbvie INC. | $199.17 | 2019-2022 | |
| Lilly USA, LLC | $193.90 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $147.92 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $140.60 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.56 | 2019-2020 | |
| Glaxosmithkline, LLC. | $77.54 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $77.24 | 2019 | |
| Sanofi Pasteur INC. | $67.41 | 2019-2020 | |
| Amarin Pharma, INC. | $52.78 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $52.26 | 2019-2020 | |
| Astellas Pharma US INC | $48.44 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $47.41 | 2020 | |
| Mannkind Corporation | $36.99 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.91 | 2019-2020 | |
| Allergan, INC. | $30.66 | 2019 | |
| Novartis Pharmaceuticals Corporation | $29.74 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $25.43 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $23.64 | 2019-2020 | |
| Daiichi Sankyo INC. | $19.35 | 2019 | |
| Ibsa Pharma INC. | $15.40 | 2020 | |
| Abbott Laboratories | $14.15 | 2019 | |
| Philips North America LLC | $12.64 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.